Merus (NASDAQ:MRUS) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, September 18th, BidAskClub reports.
MRUS has been the subject of several other research reports. Roth Capital assumed coverage on shares of Merus in a research report on Friday, June 28th. They issued a “buy” rating and a $20.00 price objective for the company. Zacks Investment Research raised shares of Merus from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Merus currently has a consensus rating of “Buy” and a consensus target price of $23.43.
Shares of MRUS traded down $0.01 on Wednesday, hitting $16.42. 69,149 shares of the stock traded hands, compared to its average volume of 63,815. The firm has a market capitalization of $373.11 million, a P/E ratio of -8.92 and a beta of 0.24. The stock’s 50 day moving average is $17.14 and its two-hundred day moving average is $15.29. Merus has a 1 year low of $11.00 and a 1 year high of $20.95.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Morgan Stanley grew its holdings in Merus by 3.1% during the 2nd quarter. Morgan Stanley now owns 92,776 shares of the biotechnology company’s stock valued at $1,359,000 after purchasing an additional 2,788 shares in the last quarter. Athanor Capital LP bought a new position in Merus during the 2nd quarter valued at $334,000. Artal Group S.A. boosted its stake in Merus by 16.7% during the 2nd quarter. Artal Group S.A. now owns 350,000 shares of the biotechnology company’s stock valued at $5,128,000 after acquiring an additional 50,000 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Merus by 63.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology company’s stock worth $123,000 after buying an additional 3,389 shares during the last quarter. Finally, Granite Investment Partners LLC bought a new position in shares of Merus in the 1st quarter worth about $468,000. 52.00% of the stock is owned by institutional investors and hedge funds.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Further Reading: Death Cross
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.